Anticancer Effect of C19-Position Substituted Geldanamycin Derivatives Targeting NRF2-NQO1-activated Esophageal Squamous Cell Carcinoma.

In esophageal squamous cell carcinoma, genetic activation of NRF2 increases resistance to chemotherapy and radiotherapy, which results in a significantly worse prognosis for patients. Therefore NRF2-activated cancers create an urgent clinical need to identify new therapeutic options. In this context, we previously identified the geldanamycin family of HSP90 inhibitors, which includes 17DMAG, to be synthetic lethal with NRF2 activity.

Decreased Sleep Duration and Increased Use of Medication to Aid Sleep Among Parents of Children With Atopic Dermatitis: A Cross-Sectional Study of the National Health Interview Survey, 2013-2018.

While atopic dermatitis (AD) is one of the most common childhood inflammatory conditions and has been associated with decreased parental sleep quality, most of the reports on this topic are single-institutional in nature with relatively small sample sizes. Thus, to assess the association of childhood AD with parental sleep on a national scale, we utilized the 2013-2018 National Health Interview Survey (NHIS) and conducted multivariable logistic regression analyses. 6,130,919 (mean age: 7.

Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy.

Patient-derived tumor organoids have been leveraged for disease modeling and preclinical studies but rarely applied in real time to aid with interpretation of patient treatment responses in clinics. We recently demonstrated early efficacy signals in a first-in-human, phase 1 study of dual-targeting chimeric antigen receptor (CAR)-T cells (EGFR-IL13Rα2 CAR-T cells) in patients with recurrent glioblastoma. Here, we analyzed six sets of patient-derived glioblastoma organoids (GBOs) treated concurrently with the same autologous CAR-T cell products as patients in our phase 1 study.